KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of $7.45 million. The enterprise value is $216,818.
| Market Cap | 7.45M |
| Enterprise Value | 216,818 |
Important Dates
The next estimated earnings date is Wednesday, November 18, 2026, before market open.
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KALA BIO has 19.34 million shares outstanding. The number of shares has increased by 6,874.92% in one year.
| Current Share Class | 19.34M |
| Shares Outstanding | 19.34M |
| Shares Change (YoY) | +6,874.92% |
| Shares Change (QoQ) | +28.75% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 4.07% |
| Float | 19.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.88
| Current Ratio | 6.88 |
| Quick Ratio | 4.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.11 |
Financial Efficiency
Return on equity (ROE) is -345.32% and return on invested capital (ROIC) is -85.30%.
| Return on Equity (ROE) | -345.32% |
| Return on Assets (ROA) | -65.43% |
| Return on Invested Capital (ROIC) | -85.30% |
| Return on Capital Employed (ROCE) | -269.89% |
| Weighted Average Cost of Capital (WACC) | -9.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.68M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.43% in the last 52 weeks. The beta is -2.41, so KALA BIO's price volatility has been lower than the market average.
| Beta (5Y) | -2.41 |
| 52-Week Price Change | -99.43% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 9.83 |
| Relative Strength Index (RSI) | 30.66 |
| Average Volume (20 Days) | 3,692,413 |
Short Selling Information
The latest short interest is 445,421, so 2.30% of the outstanding shares have been sold short.
| Short Interest | 445,421 |
| Short Previous Month | 403,121 |
| Short % of Shares Out | 2.30% |
| Short % of Float | 2.30% |
| Short Ratio (days to cover) | 0.62 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.41M |
| Pretax Income | -10.08M |
| Net Income | -10.08M |
| EBITDA | -24.07M |
| EBIT | -24.41M |
| Earnings Per Share (EPS) | -$1.30 |
Balance Sheet
The company has $7.23 million in cash and no debt, with a net cash position of $7.23 million or $0.37 per share.
| Cash & Cash Equivalents | 7.23M |
| Total Debt | n/a |
| Net Cash | 7.23M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 9.04M |
| Book Value Per Share | 0.47 |
| Working Capital | 9.04M |
Cash Flow
In the last 12 months, operating cash flow was -$19.86 million and capital expenditures -$15,000, giving a free cash flow of -$19.88 million.
| Operating Cash Flow | -19.86M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 340,500 |
| Net Borrowing | -19.95M |
| Free Cash Flow | -19.88M |
| FCF Per Share | -$1.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6,874.92% |
| Shareholder Yield | -6,874.92% |
| Earnings Yield | -135.38% |
| FCF Yield | -266.97% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 11, 2026. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |